STOCK TITAN
  1. Home
  2. News
  3. VNDA

Vanda Pharmaceuticals Inc. - VNDA STOCK NEWS

Welcome to our dedicated page for Vanda Pharmaceuticals news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharmaceuticals stock.

Vanda Pharmaceuticals Inc., traded under the symbol VNDA on Nasdaq, is a specialty biopharmaceutical company dedicated to the development and commercialization of innovative therapies. Vanda's primary focus is on addressing high unmet medical needs to improve the lives of patients. The company's commercial portfolio includes HETLIOZ for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome, and Fanapt for schizophrenia. Recently added to its portfolio is PONVORY, a treatment for multiple sclerosis.

Other promising products in Vanda's pipeline include VHX-896, ASO Molecules, VQW-765, Tradipitant (in clinical studies for gastroparesis and motion sickness), and VTR-297. Vanda's robust R&D efforts are highlighted by substantial advancements, such as the initiation of clinical programs in conditions like depression, psoriasis, ulcerative colitis, and pediatric insomnia.

In recent financial news, Vanda reported a net loss of $4.1 million for Q1 2024, a shift from a net income of $3.3 million in Q1 2023. Despite this, the company maintains a strong cash position and expects significant growth from upcoming milestones, including the launch of Fanapt in acute bipolar I disorder and PONVORY in multiple sclerosis.

Recently, Vanda made headlines with the FDA approval of tradipitant for preventing vomiting induced by motion sickness, and the commencement of a comprehensive marketing program for PONVORY following its acquisition from a Johnson & Johnson company. Additional corporate activities involve evaluating unsolicited acquisition proposals, indicating a strategic interest in Vanda’s innovative portfolio.

For more detailed information, investors can visit www.vandapharma.com and follow Vanda on social media platforms.

News

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Rhea-AI Summary
Vanda Pharmaceuticals Inc. announced that the FDA has approved the Investigational New Drug application to evaluate VCA-894A for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S. This rare subtype of CMT has no available treatment, and the estimated prevalence of the CMT2S variant is less than 1 in 1,000,000 worldwide. VCA-894A is a novel antisense oligonucleotide that specifically targets a cryptic splice site variant within the IGHMBP2 gene, which plays a pivotal role in the manifestation of CMT2S. The treatment aims to enable personalized medicine and modulate gene expression for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
fda approval
-
News

Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration

Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) has received a partial denial from the United States Court of Federal Claims for the FDA's uncompensated taking of Vanda's trade secrets and confidential information. The claim filed in May 2023 seeks compensation for the FDA's improper communication and disclosure of trade secrets to certain generic drug manufacturers. The Court's decision on January 18, 2024, allows Vanda's takings claim to move forward, with the company now intending to engage in discovery to support its claims.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
News

Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry

Rhea-AI Summary
Vanda Pharmaceuticals Inc. announced the publication of a study on the efficacy and safety of Iloperidone in treating bipolar mania, submitted to the FDA as part of a new drug application for Fanapt. The FDA has set a target action date of April 2, 2024, for its decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs

Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) Submits Comment Letter on FDA's Draft Guidance Document
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
News

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) to present at J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
-
News

Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis

Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen). PONVORY® is approved by the FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis. In a clinical study, PONVORY® showed superiority to another approved drug for MS and was associated with fewer MRI lesions. It has a proven safety profile with over 10 years of data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
acquisition
News

Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) announced that the FDA has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. The FDA has set September 18, 2024, as the target date for its decision. If approved, tradipitant will be the first novel drug for gastroparesis in over 40 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
News

Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences

Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) to participate in Stifel 2023 Healthcare Conference on November 14 and Jefferies 2023 London Healthcare Conference on November 16, with live access on corporate website. Investors advised to register early and access archived conferences for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
-
News

Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) reports total revenues of $147.4 million in the first nine months of 2023, with a focus on pipeline advancements and regulatory plans. Despite challenges with the at-risk launch of a generic Hetlioz product, the company expects FDA decisions on two sNDAs for bipolar I disorder and insomnia in 2024. Financially, net product sales decreased by 22% compared to the same period in 2022, with HETLIOZ® net product sales declining by 34%. The company's net income improved from a loss in 2022 to $4.9 million in the first nine months of 2023, with Cash at $489.9 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.94%
Tags
earnings
News

Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023

Rhea-AI Summary
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) will release its third quarter 2023 results on November 8, 2023, after the market closes. The company will host a conference call at 4:30 PM ET on the same day to discuss the financial results and other corporate activities. The call can be accessed by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) with passcode 9774278. The call will also be broadcasted and archived on Vanda's website. A replay of the call will be available until November 15, 2023, with the call-in numbers 1-800-770-2030 (domestic) and 1-609-800-9909 (international) with passcode 9774278.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
earnings

FAQ

What is the current stock price of Vanda Pharmaceuticals (VNDA)?

The current stock price of Vanda Pharmaceuticals (VNDA) is $4.35 as of January 22, 2025.

What is the market cap of Vanda Pharmaceuticals (VNDA)?

The market cap of Vanda Pharmaceuticals (VNDA) is approximately 260.3M.

What does Vanda Pharmaceuticals Inc. specialize in?

Vanda Pharmaceuticals Inc. specializes in developing and commercializing novel therapies for high unmet medical needs.

Which products are currently in Vanda's commercial portfolio?

Vanda's commercial portfolio includes HETLIOZ, Fanapt, and PONVORY.

What is HETLIOZ used for?

HETLIOZ is used to treat Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome.

What is the latest financial update from Vanda?

Vanda reported a net loss of $4.1 million for Q1 2024, shifting from a net income of $3.3 million in Q1 2023.

What significant milestones does Vanda expect in the near future?

Upcoming milestones include the launch of Fanapt in acute bipolar I disorder and PONVORY in multiple sclerosis.

What recent product approval has Vanda received?

Vanda received FDA approval for tradipitant for preventing vomiting induced by motion sickness.

What is PONVORY, and what does it treat?

PONVORY is a treatment for multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

What recent corporate actions has Vanda undertaken?

Vanda is evaluating unsolicited acquisition proposals and has initiated comprehensive marketing for PONVORY.

How can investors access Vanda’s financial results conference call?

Investors can participate by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) with passcode 2594340, or visit Vanda's website.

Where can I find more information about Vanda Pharmaceuticals?

More information can be found on Vanda's official website, www.vandapharma.com, and their social media platforms.
Stock VNDA logo
Vanda Pharmaceuticals Inc.

Nasdaq:VNDA

VNDA Rankings

#3699 Ranked by Market Cap
N/A Ranked by Dividends

VNDA Stock Data

260.35M
56.47M
3.15%
78.4%
5.38%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WASHINGTON